Pagnesi, Matteo
Adamo, Marianna
Sama, Iziah E.
Anker, Stefan D.
Cleland, John G.
Dickstein, Kenneth
Filippatos, Gerasimos S.
Inciardi, Riccardo M.
Lang, Chim C.
Lombardi, Carlo M.
Ng, Leong L.
Ponikowski, Piotr
Samani, Nilesh J.
Zannad, Faiez
van Veldhuisen, Dirk J.
Voors, Adriaan A.
Metra, Marco http://orcid.org/0000-0001-6691-8568
Funding for this research was provided by:
European Commission (FP7-242209-BIOSTAT-CHF, EudraCT 2010–020808–29)
Article History
Received: 4 December 2021
Accepted: 10 February 2022
First Online: 16 March 2022
Change Date: 24 July 2022
Change Type: Update
Change Details: In this article the following funding information was added: Open access funding provided by Università degli Studi di Brescia within the CRUI-CARE Agreement.
Declarations
:
: Dr. Filippatos reports speaker honoraria and/or committee membership in trials and/or registries sponsored by Amgen, Bayer, Novartis, Boehringer Ingrelheim, Medtronic, Vifor, and Servier; and research grants from the European Union. Dr. Voors received consultancy fees and/or research grants from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Merck, Myokardia, Novartis, Novonordisk, and Roche Diagnostics. Dr. Metra received personal consulting honoraria from Abbott, Actelion, Amgen, Bayer, Edwards Therapeutics, Servier, Vifor Pharma, and Windtree Therapeutics for participation to advisory board meetings and executive committees of clinical trials. All the other authors have no conflicts of interest to disclose.